- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04186338
Daily Physical Activity in Myelomeningocele
4. december 2019 opdateret af: Kardelen Gencer Atalay, Marmara University
Daily Physical Activity in Children and Adolescents With Low Lumbar and Sacral Level Myelomeningocele
Obesity is getting more common and challenging to treat in children and adolescents with myelomeningocele.
Therefore, it is becoming more important to determine daily physical activity in these patients.
Daily walking performance and average steps per day in patients with low lumbar and sacral level myelomeningocele are shown to not differ from healthy controls.
Step counts can not reflect all torsional accelerations associated with daily living activities.
Omnidirectional accelerometers provide all types of body movement outputs and give detailed parameters of physical activity level and energy expenditure.
There is no data about energy expenditure and physical activity level of the patients with myelomeningocele in daily routine.
This study aims to quantify energy expenditure and physical activity of children and adolescents with low lumbar and sacral level myelomeningocele.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Children and adolescents with low lumbar and sacral level myelomeningocele, and age-, sex-, and BMI-matched controls were included.
Omnidirectional accelerometer monitor (Actical®) was used to assess activity energy expenditure and daily durations spent in sedentary, light activity and moderate to vigorous physical activity (MVPA).
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
20
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
6 år til 16 år (Barn)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Sandsynlighedsprøve
Studiebefolkning
Children and adolescents with low lumbar and sacral level myelomeningocele and their age-, sex-, and body mass index (BMI)-matched healthy peers were included.
Beskrivelse
Inclusion Criteria:
- Patients diagnosed myelomeningocele with the neurological level between L5 and S3
- Patients aged between 6 and 16 years
- Independent ambulatory patients without an assistive device or braces
Exclusion Criteria:
- Presence of disorders other than myelomeningocele that affect physical activity or exercise (e.g. rheumatic disease, cardiovascular disease)
- Unable to wear omnidirectional accelerometer monitor (Actical®, Philips Respironics) for five consecutive days
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Patients with myelomeningocele
Patients diagnosed myelomeningocele with the neurological level between L5 and S3
|
All participants were instructed to wear monitors for five consecutive days except during water-based activities.
Data for each participant was collected to ensure included three valid weekdays.
Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
|
|
Healthy controls
age-, sex-, and body mass index-matched healthy controls
|
All participants were instructed to wear monitors for five consecutive days except during water-based activities.
Data for each participant was collected to ensure included three valid weekdays.
Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Average Activity energy expenditure (AEE)
Tidsramme: After wearing monitors for five consecutive days
|
Activity energy expenditure (AEE) (kcal/kg/min) refers to thermogenesis from all activities associated with daily living.
An average amount of three valid weekdays will be calculated.
|
After wearing monitors for five consecutive days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Average physical activity durations
Tidsramme: After wearing monitors for five consecutive days
|
The sedentary level (min) is the total amount of time when AEE below 0.01 kcal/kg/min.
The light level is the total amount of time when AEE between 0.01 and 0.04 kcal/kg/min.
The moderate level is the total amount of time when AEE between 0.04 and 0.10 kcal/kg/min.
The vigorous level (min) is the total amount of time when AEE above 0.10 kcal/kg/min.
|
After wearing monitors for five consecutive days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Kardelen Gencer Atalay, Marmara University
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. december 2016
Primær færdiggørelse (Faktiske)
1. april 2017
Studieafslutning (Faktiske)
1. maj 2017
Datoer for studieregistrering
Først indsendt
2. december 2019
Først indsendt, der opfyldte QC-kriterier
2. december 2019
Først opslået (Faktiske)
4. december 2019
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
6. december 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
4. december 2019
Sidst verificeret
1. december 2019
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 09.2017.168
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fysisk aktivitet
-
University of ValenciaAktiv, ikke rekrutterendeAutismespektrumforstyrrelse | Attention Deficit Hyper ActivitySpanien
-
NYU Langone HealthAfsluttetAttention Deficit Hyper ActivityForenede Stater
-
Texas Woman's UniversityAfsluttetIntellektuel handicap | Autismespektrumforstyrrelse | Motoriske lidelser | Motorforsinkelse | Sanseforstyrrelser | Attention Deficit Hyper Activity
-
Cingulate TherapeuticsPremier Research Group plcAfsluttetADHD | Attention Deficit Hyperactivity Disorder | ADHD - kombineret type | Attention Deficit Hyperactivity Disorder kombineret | Attention Deficit Hyper Activity | Opmærksomhedsunderskud hyperaktivitetForenede Stater
-
Cingulate TherapeuticsSuspenderetADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder med hyperaktivitet | ADHD - kombineret type | Attention Deficit Hyperactivity Disorder kombineret | Attention Deficit Hyper Activity | Opmærksomhedsunderskud hyperaktivitetForenede Stater
-
Affiliated Hospital to Academy of Military Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking...RekrutteringAldersinterval ≥16 år, køn ubegrænset | Histopatologi bekræftet diffust stort B-celle lymfom eller højgradigt B-celle lymfom | Modtaget tidligere førstelinjekemoterapi for DLBCL eller HGBL, kunne ikke nå CR i fire cyklusser eller tilbagefald | Mindst én positiv læsion ifølge 2014 Lugano-kriterierne... og andre forholdKina